Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting

Completed · Phase 4 · Has a placebo group

Conditions studied: Corona Virus Infection

In brief

This is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk COVID-19 positive outpatient population.

Key facts

Study ID

NCT04621461

Run by

St. Francis Hospital, New York

People needed

3

Starts

2020-12-20

Expected to finish

2021-02-08

Last updated by the study team

2021-02-11

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to read and understand informed consent.
• High initial clinical suspicion by physician based on signs and symptoms (fever, cough, myalgias, fatigue, shortness of breath) followed by confirmation of COVID-19 diagnosis
• Any gender
• Age 60 years and older
• Age 30-59 years with one or more of the following:
• abnormal lung exam
• abnormal oxygen saturation <95%
• abnormal Chest X-ray or chest CT
• persistent fever >100.4 degrees Fahrenheit
• one of the following co-morbidities: hypertension, diabetes mellitus, history of coronary artery disease, chronic kidney disease (CKD), asthma, COPD, current or former smoker, or morbid obesity (Body Mass Index ≥35)

You may not qualify if…

• Severe COVID-19 requiring admission for inpatient treatment
• Need for any oxygen supplementation
• Need for mechanical ventilatory support
• History of oxygen supplementation dependency
• History of cancer with ongoing chemotherapy or radiation therapy
• Known hypersensitivity to zinc
• Severe renal disease: Glomerular Filtration Rate <30ml/min

Where it is running

• St. Francis Hospital - The Heart Center — Roslyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.